Literature DB >> 19926371

Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

Helen L MacLaughlin1, Sharlene A Cook, Deepa Kariyawasam, Magnus Roseke, Marcelle van Niekerk, Iain C Macdougall.   

Abstract

BACKGROUND: Obesity increases the comorbidity-adjusted relative risk of developing end-stage renal disease. Body mass index (BMI) > 30 kg/m(2) was a contraindication for transplant in our renal unit until 2008. STUDY
DESIGN: Open-label prospective nonrandomized intervention. SETTING & PARTICIPANTS: All men and women aged 18-75 years with chronic kidney disease (CKD) and BMI > 30 or > 28 kg/m(2) with diabetes, hypertension, or dyslipidemia and otherwise suitable for kidney transplant if on dialysis therapy were eligible to enroll in the weight-management program. 64 patients were referred; 44 agreed to participate in the intervention group and 20 did not wish to take part and constitute the usual-care group. INTERVENTION: 24-month weight-management program that included a low-fat renal-specific diet, exercise, and orlistat, 120 mg, 3 times daily. OUTCOMES: Body weight, blood pressure (BP), kidney transplant wait listing. MEASUREMENTS: Body weight, BP, estimated glomerular filtration rate (eGFR; calculated using the 4-variable Modification of Diet in Renal Disease [MDRD] Study equation).
RESULTS: 32 patients (73%) in the weight-management program group completed the follow-up evaluation. Baseline mean BMI was 35.7 +/- 4.5 (SD) kg/m(2) in the weight-management program group and 34.1 +/- 4.2 kg/m(2) in the usual-care group. 12 (38%) patients in the weight-management program and 9 (45%) in usual care had stages 3-4 CKD, with the remainder in stage 5 CKD on dialysis therapy. There were no differences in body weight, BP, or eGFR between groups at baseline. After 24 months, mean body weight was 94.6 +/- 16.1 kg in the weight-management program group versus 101.0 +/- 26.8 kg in the usual-care group (P < 0.001), and eGFR was 43 mL/min in the weight-management program group versus 18 mL/min in the usual-care group (P < 0.001). 9 of 26 (35%) otherwise eligible patients in the weight-management program and 1 of 18 (6%) patients in usual care were accepted for kidney transplant listing, with 3 transplants performed in the weight-management program group and 1 in the usual-care group. LIMITATIONS: Nonrandomized trial, small number of participants.
CONCLUSIONS: The weight-management program group showed significant weight loss and weight-loss maintenance in obese patients with CKD and potentially enables obese patients with CKD to undergo kidney transplant. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926371     DOI: 10.1053/j.ajkd.2009.09.011

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

Review 1.  Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome.

Authors:  Jordana B Cohen; Debbie L Cohen
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

2.  Lifestyle Intervention Has to Be Part of the Strategy in Kidney Transplant Candidate with Obesity.

Authors:  Sophie Cambos; Emilie Pupier; Maud Monsaingeon-Henry; Elias Sawaya; Karine Moreau; Blandine Gatta-Cherifi
Journal:  Obes Surg       Date:  2017-11       Impact factor: 4.129

3.  Sleeve Gastrectomy after Renal Transplantation.

Authors:  Germán Viscido; Verónica Gorodner; Franco Jose Signorini; Mario Campazzo; Luciano Navarro; Lucio Ricardo Obeide; Federico Moser
Journal:  Obes Surg       Date:  2018-06       Impact factor: 4.129

Review 4.  Current issues in the management and monitoring of hypertension in chronic kidney disease.

Authors:  Pranav S Garimella; Katrin Uhlig
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 5.  Metabolic Disorders with Kidney Transplant.

Authors:  Elizabeth Cohen; Maria Korah; Glenda Callender; Renata Belfort de Aguiar; Danielle Haakinson
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-13       Impact factor: 8.237

Review 6.  Obesity and body composition for transplant wait-list candidacy--challenging or maintaining the BMI limits?

Authors:  Kirsten L Johansen
Journal:  J Ren Nutr       Date:  2013-05       Impact factor: 3.655

Review 7.  Hidden Obesity in Dialysis Patients: Clinical Implications.

Authors:  Matthew K Abramowitz; Deep Sharma; Vaughn W Folkert
Journal:  Semin Dial       Date:  2016-05-04       Impact factor: 3.455

8.  Metabolic Syndrome Severity and Risk of CKD and Worsened GFR: The Jackson Heart Study.

Authors:  Mark D DeBoer; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D Okusa; Matthew Gurka
Journal:  Kidney Blood Press Res       Date:  2018-04-06       Impact factor: 2.687

9.  Association of walking with survival and RRT among patients with CKD stages 3-5.

Authors:  I-Ru Chen; Su-Ming Wang; Chih-Chia Liang; Huey-Liang Kuo; Chiz-Tzung Chang; Jiung-Hsiun Liu; Hsin-Hung Lin; I-Kuan Wang; Ya-Fei Yang; Che-Yi Chou; Chiu-Ching Huang
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-15       Impact factor: 8.237

Review 10.  Management of Obesity in Adults with CKD.

Authors:  Allon N Friedman; Lee M Kaplan; Carel W le Roux; Philip R Schauer
Journal:  J Am Soc Nephrol       Date:  2021-02-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.